代偿晚期慢性肝病首次代偿失代偿的无创预测模型- meta分析

IF 12 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Angus W Jeffrey, James Chen, Andrew Chin, Emmanuel A Tsochatzis, Avik Majumdar, Luis Calzadilla-Bertot, Michael C Wallace, Gary P Jeffrey, Leon A Adams
{"title":"代偿晚期慢性肝病首次代偿失代偿的无创预测模型- meta分析","authors":"Angus W Jeffrey, James Chen, Andrew Chin, Emmanuel A Tsochatzis, Avik Majumdar, Luis Calzadilla-Bertot, Michael C Wallace, Gary P Jeffrey, Leon A Adams","doi":"10.1016/j.cgh.2025.10.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>This review aimed to critically appraise available data to determine the accuracy of non-invasive prediction models (NITs) in identifying patients with cACLD who are at increased risk of a first episode of hepatic decompensation.</p><p><strong>Methods: </strong>This systematic review and meta-analysis was conducted from all published articles until February 2025. Studies were included if they evaluated performance of a NIT, defined as two or more individual non-invasive markers that had been combined into a prognostic model. Studies were excluded if analysis was done on a population that included those without cACLD, and studies examining only singular prognostic markers (including baseline liver stiffness in isolation). Summary data was extracted from published reports consisting of the c-statistic and/or AUROC and model calibration. This review was registered with PROSPERO (CRD42024608001).</p><p><strong>Results: </strong>Of 6,540 screened articles, 30 were included consisting of 47,647 participants with cACLD. The articles described 39 prognostic models; of which 19 were suitable for meta-analysis. Random effects meta-analysis found models specifically developed and validated in cACLD provide the best prediction, including the SAVE score (summary c-statistic 0.87, 95% CI 0.82-0.93) and ABC score (0.85, 0.80-0.89). There was limited validation and calibration of all models. Sensitivity analysis of cohorts using an invasive diagnosis for cACLD provided the least heterogeneous outcomes, with all assessed models having an I<sup>2</sup> < 50%.</p><p><strong>Conclusions: </strong>CACLD specific NITs offer the best option in predicting decompensation, and future studies should focus on robust validation, calibration and external validation with standardised endpoints to ensure that models are reliable for guiding clinical practice in applicable populations.</p>","PeriodicalId":10347,"journal":{"name":"Clinical Gastroenterology and Hepatology","volume":" ","pages":""},"PeriodicalIF":12.0000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Non-Invasive Prediction Models of First Decompensation in Compensated Advanced Chronic Liver Disease - A Meta-Analysis.\",\"authors\":\"Angus W Jeffrey, James Chen, Andrew Chin, Emmanuel A Tsochatzis, Avik Majumdar, Luis Calzadilla-Bertot, Michael C Wallace, Gary P Jeffrey, Leon A Adams\",\"doi\":\"10.1016/j.cgh.2025.10.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and aims: </strong>This review aimed to critically appraise available data to determine the accuracy of non-invasive prediction models (NITs) in identifying patients with cACLD who are at increased risk of a first episode of hepatic decompensation.</p><p><strong>Methods: </strong>This systematic review and meta-analysis was conducted from all published articles until February 2025. Studies were included if they evaluated performance of a NIT, defined as two or more individual non-invasive markers that had been combined into a prognostic model. Studies were excluded if analysis was done on a population that included those without cACLD, and studies examining only singular prognostic markers (including baseline liver stiffness in isolation). Summary data was extracted from published reports consisting of the c-statistic and/or AUROC and model calibration. This review was registered with PROSPERO (CRD42024608001).</p><p><strong>Results: </strong>Of 6,540 screened articles, 30 were included consisting of 47,647 participants with cACLD. The articles described 39 prognostic models; of which 19 were suitable for meta-analysis. Random effects meta-analysis found models specifically developed and validated in cACLD provide the best prediction, including the SAVE score (summary c-statistic 0.87, 95% CI 0.82-0.93) and ABC score (0.85, 0.80-0.89). There was limited validation and calibration of all models. Sensitivity analysis of cohorts using an invasive diagnosis for cACLD provided the least heterogeneous outcomes, with all assessed models having an I<sup>2</sup> < 50%.</p><p><strong>Conclusions: </strong>CACLD specific NITs offer the best option in predicting decompensation, and future studies should focus on robust validation, calibration and external validation with standardised endpoints to ensure that models are reliable for guiding clinical practice in applicable populations.</p>\",\"PeriodicalId\":10347,\"journal\":{\"name\":\"Clinical Gastroenterology and Hepatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":12.0000,\"publicationDate\":\"2025-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Gastroenterology and Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cgh.2025.10.002\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Gastroenterology and Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cgh.2025.10.002","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:本综述旨在批判性地评估现有数据,以确定非侵入性预测模型(NITs)在识别首次肝代偿发作风险增加的cACLD患者中的准确性。方法:对截至2025年2月的所有已发表的文章进行系统评价和荟萃分析。如果研究评估了NIT的表现,则纳入研究,NIT的定义是两个或多个单独的非侵入性标志物组合成预后模型。如果对包括没有cACLD的人群进行分析,以及仅检查单一预后标志物(包括孤立的基线肝硬度)的研究被排除。摘要数据从已发表的报告中提取,包括c统计量和/或AUROC和模型校准。本综述已在普洛斯彼罗注册(CRD42024608001)。结果:在6540篇筛选文章中,纳入了30篇,包括47647名cld患者。文章描述了39种预测模型;其中19个适合进行meta分析。随机效应荟萃分析发现,在cACLD中专门开发和验证的模型提供了最好的预测,包括SAVE评分(总c统计量0.87,95% CI 0.82-0.93)和ABC评分(0.85,0.80-0.89)。所有模型的验证和校准都是有限的。使用侵入性诊断cld的队列的敏感性分析提供了最少的异质性结果,所有评估模型的I2 < 50%。结论:CACLD特异性nit是预测失代偿的最佳选择,未来的研究应侧重于具有标准化终点的稳健验证、校准和外部验证,以确保模型在适用人群中指导临床实践的可靠性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Non-Invasive Prediction Models of First Decompensation in Compensated Advanced Chronic Liver Disease - A Meta-Analysis.

Background and aims: This review aimed to critically appraise available data to determine the accuracy of non-invasive prediction models (NITs) in identifying patients with cACLD who are at increased risk of a first episode of hepatic decompensation.

Methods: This systematic review and meta-analysis was conducted from all published articles until February 2025. Studies were included if they evaluated performance of a NIT, defined as two or more individual non-invasive markers that had been combined into a prognostic model. Studies were excluded if analysis was done on a population that included those without cACLD, and studies examining only singular prognostic markers (including baseline liver stiffness in isolation). Summary data was extracted from published reports consisting of the c-statistic and/or AUROC and model calibration. This review was registered with PROSPERO (CRD42024608001).

Results: Of 6,540 screened articles, 30 were included consisting of 47,647 participants with cACLD. The articles described 39 prognostic models; of which 19 were suitable for meta-analysis. Random effects meta-analysis found models specifically developed and validated in cACLD provide the best prediction, including the SAVE score (summary c-statistic 0.87, 95% CI 0.82-0.93) and ABC score (0.85, 0.80-0.89). There was limited validation and calibration of all models. Sensitivity analysis of cohorts using an invasive diagnosis for cACLD provided the least heterogeneous outcomes, with all assessed models having an I2 < 50%.

Conclusions: CACLD specific NITs offer the best option in predicting decompensation, and future studies should focus on robust validation, calibration and external validation with standardised endpoints to ensure that models are reliable for guiding clinical practice in applicable populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
16.90
自引率
4.80%
发文量
903
审稿时长
22 days
期刊介绍: Clinical Gastroenterology and Hepatology (CGH) is dedicated to offering readers a comprehensive exploration of themes in clinical gastroenterology and hepatology. Encompassing diagnostic, endoscopic, interventional, and therapeutic advances, the journal covers areas such as cancer, inflammatory diseases, functional gastrointestinal disorders, nutrition, absorption, and secretion. As a peer-reviewed publication, CGH features original articles and scholarly reviews, ensuring immediate relevance to the practice of gastroenterology and hepatology. Beyond peer-reviewed content, the journal includes invited key reviews and articles on endoscopy/practice-based technology, health-care policy, and practice management. Multimedia elements, including images, video abstracts, and podcasts, enhance the reader's experience. CGH remains actively engaged with its audience through updates and commentary shared via platforms such as Facebook and Twitter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信